Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | FCER2 | P06734 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8675411 | 1.00 | HDAC1 (0.53) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL6342212 | 0.84 | LMNA (0.46) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL6344345 | 0.83 | KMT2A (0.53) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL6341820 | 0.79 | KMT2A (0.45) | CYP2D6CTSDKMT2ABCAT2EPHX1 | |
| SCHEMBL31242992 | 0.78 | CYP2D6 (0.64) | CYP2D6CTSDKMT2AEPHX1LMNA | |
| SCHEMBL6212590 | 0.77 | KMT2A (0.46) | CYP2D6CTSDKMT2ABCAT2LMNA | |
| SCHEMBL6351480 | 0.77 | BACE1 (0.43) | CYP2D6CTSDKMT2ABCAT2EPHX1 | |
| SCHEMBL3704070 | 0.77 | CYP2D6 (0.56) | CYP2D6CTSDKMT2ABCAT2EPHX1 | |
| SCHEMBL6052959 | 0.74 | CYP2D6 (0.44) | CYP2D6KMT2AEPHX1LMNAMAPK1 | |
| SCHEMBL6345670 | 0.74 | RAB9A (0.52) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846820-B2 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | disclosed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | HDAC1 831/4885HDAC8 388/4885HDAC6 3064/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | HDAC1 715/4885HDAC8 405/4885HDAC6 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.